An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.
This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.
Demodex blepharitis is the leading reason that patients visit eye physicians, making up 40% to 50% of eye care professional appointments. Many patients are misdiagnosed and mistreated for aqueous-deficient dry eye with expensive immunomodulators instead of given the correct Demodex blepharitis diagnosis. Correct diagnosis and treatment with Xdemvy(lotilaner ophthalmic solution) significantly cuts costs.
Once diagnosed, Demodex blepharitis responds well to treatment. Lotilaner is a safe and effective 6-week, twice-daily course that improves ocular surface disease for at least 1 year, showing long-term stability for this previously unmanaged chronic condition.
It is important that patients understand Demodex pathogenesis because an eyelash mite infestation, in addition to clinical outcomes, usually motivates treatment adherence.
Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More